Ibrutinib is currently a standard of care in relapsed/refractory chronic lymphocytic leukemia, but zanubrutinib is an effective second-line and second-generation option, said Peter Hillmen, PhD, MB ChB, professor at the University of Leeds.
Ibrutinib is currently a standard of care in relapsed/refractory chronic lymphocytic leukemia, but zanubrutinib is an effective second-line and second-generation option, said Peter Hillmen, PhD, MB ChB, professor at the University of Leeds and honorary consultant hematologist at Leeds Teaching Hospitals NHS Trust.
Transcript
Ibrutinib is a standard of care in chronic lymphocytic leukemia. How can zanubrutinib differentiate itself as a treatment of choice?
So, I think ibrutinib is one of the standards of care, for sure, and we have a lot of mature data for ibrutinib in relapsed disease. So, it continues to be important treatment. I think we need more data and larger trials of safety for ibrutinib going forward, to look at those rare complications we see with BTK [Bruton tyrosine kinase] inhibition.
I think the zanubrutinib is an effective second-line, also second-generation, BTK inhibitor, and where available, you know, may say displace ibrutinib in some patient groups, I think. It's given twice a day, which is slightly less convenient, but most patients are fine. It can cause a little bit more neutropenia but doesn't seem to cause more infection. So, it's been, it's very well tolerated. I think it gives us more options with the number of BTK inhibitors is coming through.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More